Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Perruolo, Giuseppe ^a,b   Viggiano, Davide ^b,c   Fiory, Francesca ^a,b   Cassese, Angela ^a   Nigro, Cecilia ^a,b   Liotti, Antonietta ^a,b   Miele, Claudia ^a,b   Beguinot, Francesco ^a,b   Formisano, Pietro ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; PEA15 PROTEIN, MOUSE; PHOSPHOPROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL; ANIMAL BEHAVIOR; INSULIN RESISTANCE; MALE; MEMORY; METABOLISM; MOTOR ACTIVITY; NEOSTRIATUM; PARKINSON DISEASE; PATHOLOGY; PHENOTYPE; PUTAMEN; ROTAROD TEST; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; INSULIN RESISTANCE; MALE; MEMORY; MICE, TRANSGENIC; MOTOR ACTIVITY; NEOSTRIATUM; PARKINSON DISEASE; PHENOTYPE; PHOSPHOPROTEINS; PUTAMEN; ROTAROD PERFORMANCE TEST; TYROSINE 3-MONOOXYGENASE;

EID: 84979255279     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29967     Document Type: Article

References (37)

1. Condorelli, G. et al. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J. 17, 3858-66 (1998).
2. Valentino, R. et al. The PEA15 gene is overexpressed and related to insulin resistance in healthy first-degree relatives of patients with type 2 diabetes. Diabetologia 49, 3058-3066 (2006).
3. Vigliotta, G. et al. Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action. Mol. Cell. Biol. 24, 5005-5015 (2004).
4. Miele, C. et al. PED/PEA-15 regulates glucose-induced insulin secretion by restraining potassium channel expression in pancreatic beta-cells. Diabetes 56, 622-633 (2007).
5. Fiory, F. et al. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 297, E592-E601 (2009).
6. Araujo, H. et al. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J. Biol. Chem. 268, 5911-5920 (1993).
7. Sharif, A. et al. The expression of PEA-15 (phosphoprotein enriched in astrocytes of 15 kDa) defines subpopulations of astrocytes and neurons throughout the adult mouse brain. Neuroscience 126, 263-275 (2004).
8. Thomason, L. A. et al. Reactive astrocytes associated with plaques in TgCRND8 mouse brain and in human Alzheimer brain express phosphoprotein enriched in astrocytes (PEA-15). FEBS Lett. 587, 2448-2454 (2013).
9. Sandyk, R. The relationship between diabetes mellitus and Parkinson's disease. Int. J. Neurosci. 69, 125-130 (1993).
10. Gray, S. M., Meijer, R. I. & Barrett, E. J. Insulin regulates brain function, but how does it get there? Diabetes 63, 3992-3997 (2014).
11. Hu, G. et al. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30, 842-847 (2007).
12. Yue, X. et al. Risk of parkinson disease in diabetes mellitus: an updated meta-analysis of polpulation-based cohort studies. Medicine 95, e3549 (2016).
13. Lu, L. et al. Diabetes and risk of parkinson's disease: an updated meta-analysis of case-control studies. Plos One 9, e85781 (2014)
14. Brauer, R. et al. Glitazone tratment and incidence of Parkinon's disease among peolple with diabetes: a retrospective cohort study. Plos Med, 12, e1001854 (2015)
15. Glading, A. et al. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res. 67, 1536-1544 (2007).
16. Bae, E. J. et al. Phospholipase D1 regulates autophagic flux and clearance of ?-synuclein aggregates. Cell. Death. Differ. 21, 1132-1141 (2014).
17. Trencia, A. et al. Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea-15. J. Biol. Chem. 279, 46566-46572 (2004).
18. Strauss, K. M., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14, 2099-2111 (2005).
19. Mignogna, P. & Viggiano, D. Brain distribution of genes related to changes in locomotor activity. Physiol. Behav. 99, 618-626 (2010).
20. Iovino, S. et al. PED/PEA-15 induces autophagy and mediates TGF-beta1 effect on muscle cell differentiation. Cell Death Differ. 19, 1127-1138 (2012).
21. Zhou, Q. Y. & Palmiter, R. D. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 1197-1209 (1995).
22. Hwang, D. Y. et al. 3, 4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci. 25, 2132-2137 (2005).
23. Van den Munckhof, P. et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130, 2535-2542 (2003).
24. Strazielle, C. et al. Regional brain variations of cytochrome oxidase activity and motor coordination in Girk2 (Wv) (Weaver) mutant mice. Neuroscience 142, 437-449 (2006).
25. Shinzawa, K. et al. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J. Neurosci. 28, 2212-2220 (2008).
26. Driller, K. et al. Nuclear factor I X deficiency causes brain malformation and severe skeletal defects. Mol. Cell. Biol. 27, 3855-3867 (2007).
27. Mantamadiotis, T. et al. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31, 47-54 (2002).
28. Nishi, M. et al. Motor discoordination in mutant mice lacking junctophilin type 3. Biochem. Biophys. Res. Commun. 292, 318-324 (2002).
29. Reddy, P. H. et al. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R Soc. Lond. B Biol. Sci. 354, 1035-1045 (1999).
30. Colomer Gould, V. F. Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease). Neurotherapeutics 9, 285-296 (2012).
31. Lalonde, R., Qian, S. & Strazielle, C. Transgenic mice expressing the PS1-A246E mutation: effects on spatial learning, exploration, anxiety, and motor coordination. Behav. Brain Res. 138, 71-79 (2003).
32. Trushina, E. et al. Neurological abnormalities in caveolin-1 knock out mice. Behav. Brain Res. 172, 24-32 (2006).
33. Brunskill, E. W. et al. Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice. Eur. J. Neurosci. 22, 1265-1276 (2005).
34. Chiu, C.-S. et al. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J. Neurosci. 25, 3234-3245 (2005).
35. Kan, L. et al. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 165, 1107-1115 (2004).
36. Ramos, J. W. et al. Deletion of PEA-15 in mice is associated with specific impairments of spatial learning abilities. BMC Neurosci. 10, 134 (2009).
37. Ahn, E. H. et al. PEP-1-PEA-15 protects against toxin-induced neuronal damage in a mouse model of Parkinson's disease. Biochim. Biophys. Acta. 1840, 1686-1700 (2014).